Kirsten Vang Nielsen

List of Publications by Citations

20 papers	564 citations	15 h-index	20 g-index
20 ext. papers	594 ext. citations	5.6 avg, IF	2.78 L-index

#	Paper	IF	Citations
20	The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. *Acta Oncologica*, **2008**, 47, 725-34	3.2	89
19	Short PNA molecular beacons for real-time PCR allelic discrimination of single nucleotide polymorphisms. *Molecular and Cellular Probes*, **2004**, 18, 117-22	3.3	55
18	Telomere shortening and chromosomal instability in myelodysplastic syndromes. *Genes Chromosomes and Cancer*, **2010**, 49, 260-9	5	50
17	Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 345-55	4.4	47
16	Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. *Clinical Cancer Research*, **2013**, 19, 1281-9	12.9	46
15	Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. *Histopathology*, **2010**, 56, 203-11	7.3	35
14	Aberrations of ERBB2 and TOP2A genes in breast cancer. *Molecular Oncology*, **2010**, 4, 161-8	7.9	29
13	Tissue context-activated telomerase in human epidermis correlates with little age-dependent telomere loss. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2009**, 1792, 297-308	6.9	28
12	Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. *Archives of Pathology and Laboratory Medicine*, **2011**, 135, 1010-6	5	27
11	TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. *Scandinavian Journal of Gastroenterology*, **2012**, 47, 68-79	2.4	22
10	Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. *Scandinavian Journal of Gastroenterology*, **2012**, 47, 340-55	2.4	21
9	Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis. *Molecular Oncology*, **2013**, 7, 101-11	7.9	20
8	Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort. *PLoS ONE*, **2013**, 8, e60613	3.7	20
7	Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. *Molecular Oncology*, **2012**, 6, 88-97	7.9	16
6	Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody. *Scientific Reports*, **2014**, 4, 4313	4.9	15
5	ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. *Molecular Oncology*, **2012**, 6, 428-36	7.9	15
4	SNP genotyping using microsphere-linked PNA and flow cytometric detection **2005**, 64, 80-6		14

List of Publications

3   Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. *Journal of the National Cancer Institute*, **2011**, 103, 352-3   9.7   7

2   Human epidermal growth factor receptor 2 testing in breast cancer. *Journal of Clinical Oncology*, **2007**, 25, 4020; author reply 4021-3   2.2   5

1   An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort. *BMC Cancer*, **2013**, 13, 489   4.8   3